Comparative Pharmacology
Head-to-head clinical analysis: DEPACON versus FELBATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPACON versus FELBATOL.
DEPACON vs FELBATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
None Documented
None Documented
10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant